Isobolographic Analysis for Combinations of a Full and Partial Agonist: Curved Isoboles
Top Cited Papers
- 1 September 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 310 (3) , 981-986
- https://doi.org/10.1124/jpet.104.067264
Abstract
Combinations of drugs are frequently used therapeutically to achieve an enhanced effect without using an excess quantity of either agent. If the drugs exert overtly similar action, e.g., two analgesics, the effect of the combination may be tested for additivity, i.e., an effect level that is achieved based on the individual drug potencies. But combinations of agonists will sometimes display either superadditive (synergistic) or subadditive responses. Whether the two agonists are both drugs, or a combination of a drug and an endogenous chemical, there is interest in characterizing the interaction to determine whether it departs from additivity because quantitative information of this kind, aside from its therapeutic importance, may also illuminate mechanism. A common method for this characterization uses the isobologram. This is a plot in rectangular coordinates of dose combinations (a,b) that produce the same effect level (often taken to be 50% of the maximum). In its usual form, this plot is constructed as a straight line (of additivity) connecting intercepts that represent the individually effective doses, e.g., ED50 values of each. This line is the reference for distinguishing additive from nonadditive interactions accordingly as the tested combination is on or off this line. Discussed here are the assumptions that underlie this linear plot. Specifically we show that a combination of drugs with a variable potency ratio, exemplified by a full and a partial agonist, lead to curvilinear isoboles of additivity that may erroneously be attributed to either synergism or subadditivity.Keywords
This publication has 8 references indexed in Scilit:
- Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral AdministrationThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Activity of opioid ligands in cells expressing cloned mu opioid receptorsBMC Pharmacology, 2003
- N-Methyl-d-aspartate Antagonists and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 H-pyrrolo[3,2,1-i,j]quinolin-6-one], a Cannabinoid Agonist, Interact to Produce Synergistic HypothermiaThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Synergy between μ Opioid Ligands: Evidence for Functional Interactions among μ Opioid Receptor SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Gabapentin and the Neurokinin1 Receptor Antagonist CI-1021 Act Synergistically in Two Rat Models of Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Drug Synergism and Dose-Effect Data AnalysisPublished by Taylor & Francis ,2000
- Statistical analysis of drug combinations for synergismPain, 1992
- Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interactionEuropean Journal of Pharmacology, 1990